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Mortality from adult bacterial meningitis exceeds 50% in sub-
Saharan Africa. We postulated thatdparticularly in in-
dividuals infected with human immunodeficiency virus
(HIV)dherpes simplex virus, varicella zoster virus, Epstein-
Barr virus (EBV), and cytomegalovirus (CMV) in the cere-
brospinal fluid (CSF) contribute to poor outcome. CSF from
149 Malawian adults with bacterial meningitis and 39 controls
were analyzed using polymerase chain reaction. EBV was de-
tected in 79 of 149 bacterial meningitis patients. Mortality
(54%) was associated with higher CSF EBV load when adjusted
for HIV (P5 .01). CMVwas detected in 11 of 115 HIV-infected
patients, 8 of whom died. The mechanisms by which EBV and
CMV contribute to poor outcome require further investigation.
Bacterial meningitis in adults in Malawi, as in many sub-
Saharan African countries outside the ‘‘meningitis belt,’’ is
associated with a mortality exceeding 50%, even following
effective antibiotic therapy [1, 2]. One potentially important
factor in bacterial meningitis previously not investigated is the
role of coinfection of the brain with herpesviruses, particularly
in individuals who are infected with human immunodeficiency
virus (HIV). Herpesviruses infect .90% of the world’s pop-
ulation and persist indefinitely in a latent form [3]. Both pri-
mary infection and reactivation can cause neurological disease,
including meningitis and encephalitis. Reactivation may oc-
cur at any time but is particularly common during concurrent
illness or immunosuppression [4]. In Malawi .80% of adult
bacterial meningitis occurs in HIV-infected patients who
frequently have advanced immunosuppression [1]. We hy-
pothesized that in the context of this immunodeficiency, the
inflammatory process associated with bacterial meningitis
triggers reactivation of herpesviruses in the central nervous
system (CNS). Herpesvirus reactivation may alter the host
inflammatory response [5], which is known to be the pre-
dominant cause of cerebral injury in meningitis [6], and thus
contribute to poor outcome. The aim of this study was to
describe the prevalence of herpes simplex virus types 1 and
2 (HSV1&2), varicella zoster virus (VZV), Epstein-Barr virus
(EBV), and cytomegalovirus (CMV) in the cerebrospinal fluid
(CSF) of adults with bacterial meningitis in Malawi, and to
determine whether the presence of these viruses in the CSF
is associated with increased mortality.
Methods
Queen Elizabeth Hospital in Blantyre, Malawi, is a teaching
hospital offering free services to a population of approxi-
mately 1 million. From 2006 until 2009, 3 prospective adult
(age $16 years) meningitis studies were conducted at the
hospital; a randomized controlled trial of adjunctive oral
glycerol in bacterial meningitis (n 5 265) [7] and descriptive
studies of suspected meningitis of any cause (n5 573) [8] and
suspected bacterial meningitis (n 5 161) (unpublished). CSF
samples were stored at the time of diagnostic lumbar punc-
ture. Blood samples were also obtained from participants in
the randomized trial. Patients or their legal guardians gave
written informed consent before recruitment. Each study was
approved by the University of Malawi, College of Medicine
Research Ethics Committee (P.04/05/363, P.05/06/471, P.09/
08/700) and complied with all institutional guidelines. Pa-
tients were included in this study if they had an available CSF
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sample, documented HIV status, and bacterial meningitis
defined as a CSF white cell count $100 cells/mm3 with poly-
morphs.50%, or a positive CSF Gram stain, bacterial culture, or
Streptococcus pneumoniae polymerase chain reaction (PCR) test
[9]. Defining bacterial meningitis using the above CSF white
cell criteria identifies patients with the same clinical charac-
teristics and outcomes as patients with microbiologically
proven bacterial meningitis in this setting [1]. Controls were
patients from one of the descriptive studies who did not have
meningitis based on a CSF white cell count,5 cells/mm3 and
negative CSF Gram stain, cryptococcal antigen test, bacterial
culture, and mycobacterial culture.
Samples were stored at 270C until DNA extraction from
200 lL using a DNA Mini Kit (Qiagen). Five microliters of
extract was used for all assays except the CMV assay, which
is optimized for use with 10 lL [10]. Real-time PCR was
performed with an ABI7300 machine using TaqMan Master
Mix (Applied Biosystems). Primers and probes targeting con-
served regions of the DNA polymerase gene were used for
HSV1&2 (forward-GACAGCGAATTCGAGATGCTG, reverse-
ATGTTGTACCCGGTCACGAACT, HSV1 probe; 5#-FAM-
CATGACCCTTGTGAAACA-MGB-3#-BHQ1, HSV2 probe;
5#-VIC-TGACCTTCGTCAAGCAG-MGB-3#-BHQ1) and VZV
(forward-GCGCGGTAGTAACAGAGAATTTC, reverse-
ACGTGCATGGACCGGTTAAT, probe; 5#-FAM-ACCATG-
TCATCGTTTCAA-MGB-3#-BHQ1). For VZV a selection of
samples were also confirmed with a commercial VZV assay
(Qiagen). The EBV assay targeted the BNRF1 gene, and the CMV
assay targeted the UL123/UL55 genes [10, 11]. PCR conditions
were activation of UNG 50oC for 2 minutes, activation of Taq
95oC for 15 minutes, amplification for 45 cycles at 95oC for
15 seconds, and 60oC for 1 minute. Each assay had a lower
limit of detection of 1000 copies/mL assessed as the level at
which the PCR reaction always gave a positive result. Positive
controls consisted of extracted whole virus suspension (Na-
tional Institute of Biological Standards and Controls, United
Kingdom). A positive control for the virus being tested and
a negative control were tested in each run. Clinical samples
were analyzed in triplicate. Virus detection in $2 of 3 wells
was considered positive. If virus was detected in 1 of 3 wells,
the test was repeated and considered positive if it again
yielded $1 of 3 wells positive. Samples positive for EBV were
analyzed by quantitative PCR to determine EBV load using
a plasmid-derived standard. The standard was quantified by
ultraviolet spectrophotometry, serially diluted to 103–109
copies/mL, and optimized to 92% efficiency. EBV load was
also quantified in matched whole blood samples where
available.
Statistical analysis was performed using Stata software,
version 10, with a level of significance of P , .05. Medians were
compared using Wilcoxon rank-sum test. Associations were
examined using Fisher exact test, stratified Cochran-Mantel-
Haenszel tests, and logistic regression. Correlations were tested
using Spearman rank correlation.
Results
CSF samples from 188 patients were analyzed. In total, 149 (of
whom 115 were HIV positive) had bacterial meningitis and
39 (of whom 24 were HIV positive) had no meningitis (Table 1).
CD4 testing was not routinely available in Malawi during the
studies; however, where documented, there was no differ-
ence between samples with bacterial meningitis (n5 45) and
those without meningitis (n5 23) (median 188 cells/mm3 vs
157 cells/mm3, respectively; P5 .43). For patients with bacterial
meningitis the CSF white cell count was lower in HIV-positive
patients than in HIV-negative patients (median 365 cells/mm3
vs 960 cells/mm3; P 5 .009).
Nine of the 90 positive PCR results were based on repeat
testing following an initial result of 1 of 3 wells being positive
(2 HSV1, 1 CMV, 6 EBV). Reclassifying these results as negative
did not change the results of the statistical analyses.
HSV1 was detected in 2 of 39 patients without meningitis and
1 of 129 patients with bacterial meningitis (Table 1). HSV2 and
VZV were not detected in any patients.
CMV was detected in 11 of 115 (10%) HIV-positive patients
with bacterial meningitis (median CD4 count, 121 cells/mm3
[range, 1–251 cells/mm3]; n 5 7) but was not detected in any
HIV-negative patients with bacterial meningitis or 39 patients
without meningitis.
EBV was found in the CSF in 79 of 149 (53%) patients with
bacterial meningitis and was strongly associated with HIV se-
ropositivity (odds ratio 5.2 [95% confidence interval, 2.2–11.9];
P , .001). In HIV-positive patients with bacterial meningitis,
there was no correlation between CSF EBV load and CSF white
cell count (q 5 20.01, P 5 .94), CSF lymphocyte count
(q 5 20.02, P 5 .86) or CSF red cell count (q 5 20.01,
P5 .98). For those bacterial meningitis patients with CD4 count
data available there was no difference in the CD4 count between
those with (n 5 33) and without (n 5 12) EBV in the CSF
(median, 180 cells/mm3 vs 141 cells/mm3, respectively; P5 .78)
and CSF EBV load did not correlate with the CD4 count
(q 5 0.01, P 5 .97).
In HIV-positive patients without meningitis, EBV was present
in 6 of 24 (25%) patients, which was significantly less than in
those with bacterial meningitis (P5 .002). All had relatively low
EBV loads (range, 182–2281 copies/mL). EBV was not detected
in any of the 15 HIV-negative patients without meningitis.
In-hospital mortality from bacterial meningitis was higher in
HIV-positive (59% [64 of 108]) than HIV-negative (35% [12 of
34]) individuals (P 5 .016). Outcome data were unavailable for
7 HIV-positive patients. The presence of EBV in the CSF of
HIV-positive patients was not associated with outcome
(P 5 .32); however, when outcome was analyzed according to
CSF EBV load, adjusting for HIV status, there was a significant
association with mortality (P 5 .012) (Figure 1). When this
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analysis was repeated excluding those who had no EBV in the
CSF (n 5 75), the association remained (P 5 .018). Similarly,
the association remained significant when other factors pre-
viously shown to be associated with poor outcome (age
$32 years, Glasgow Coma Score ,12, hemoglobin ,10 g/dL)
[1] were included in the model (P 5 .003).
EBV load in the blood was measured in 107 bacterial men-
ingitis patients and detected in 80 of 83 (96%) HIV-positive
patients compared with 14 of 24 (58%) HIV-negative patients
(P , .001). Unlike the CSF, blood EBV load was not associated
with outcome, adjusting for HIV status (P 5 .37) (Figure 1).
Blood EBV load was higher than the corresponding CSF load for
all but 6 individuals, 3 of whom had no detectable EBV in the
blood. Of these 6 patients CSF white cell counts ranged from 120
to 5920 cells/mm3, blood white cell counts ranged from 4.5 to
22.2 cells/L, and 3 patients died.
In total, 8 of 10 patients with CMV died (outcome data were
unavailable for 1 patient). All 8 patients who died had dual
infection with EBV, whereas the 2 survivors did not. Although
the presence of CMV did not increase the risk of death (P5 .19),
EBV/CMV dual infection was associated with death (P 5 .02).
Discussion
The cerebral injury that occurs in bacterial meningitis is largely
due to a host-mediated inflammatory response [6]. Our data
suggest that this process may be amplified by EBV reactivation
and possibly CMV either in the brain or periphery. In contrast,
we show that HSV1&2 and VZV are not commonly reactivated
in adult bacterial meningitis in Malawi.
We found a very high prevalence of EBV in the context of bac-
terial meningitis, particularly in HIV-positive patients. EBV in the
CSF of HIV-positive patients is associated with CNS lymphoma,
although studies have detected EBV in other CNS diseases
[12, 13]. Replicating EBV arises from B lymphocytes in the brain
or peripheral circulation [14]. Given that we found virus in pa-
tients with no white cells in the CSF, and that replicative-cycle
EBV messenger RNA has been detected in CSF from patients with
other CNS infections [13], it is likely that some EBV was repli-
cating rather than latent. Alternatively, the inflammatory process
may allow latently infected lymphocytes into the CSF, leading
to detection of latent virus. Immunosuppressed patients have in-
creased levels of EBV in the blood due to a greater number of in-
fected B lymphocytes [3]. If reactivation occurs in the circulation,
then the disrupted blood-CSF barrier in meningitis may allow free
virus into the CSF. Although most patients had higher EBV loads
in the blood than in the CSF, the finding of higher CSF loads in
some patients suggests that EBV can arise within the CNS.
Our data show that increasing CSF EBV load is associated with
an increased risk of death from bacterial meningitis. EBV may
simply be a marker of immune impairment, although this im-
mune impairment appears to be poorly reflected in the CD4
count given the lack of correlation between CD4 count and EBV
load. Alternatively, an immune threshold may exist at which
EBV becomes detectable; however, our data show is the EBV
Table 1. Patient Characteristics and Rates of Detection of HSV 1&2, VZV, EBV, and CMV
No meningitis Bacterial meningitis
HIV negative
(n 5 15)
HIV positive
(n 5 24)
HIV negative
(n 5 34)
HIV positive
(n 5 115)
Male, no. (%) 7 (47%) 11 (46%) 22 (65%) 42 (37%)
Age, y 27 (16–77) 35 (21–50) 27 (16–79) 32 (16–78)
CD4 count,a cells/mm3 . 188 (25–553) . 157 (1–457)
Mortality (%)b NA NA 12/34 (35%) 64/108 (59%)
CSF white cell count, cells/mm3 0 0 960 (30–6160) 365 (10–72 080)
CSF PCR results (%)
HSV1 1/15 (7%) 1/24 (4%) 0/32 (0%) 1/97 (1%)
HSV2 0/15 (0%) 0/24 (0%) 0/32 (0%) 0/97 (0%)
VZV 0/15 (0%) 0/17 (0%) 0/28 (0%) 0/76 (0%)
EBV 0/15 (0%) 6/24 (25%) 9/34 (26%) 70/115 (61%)
CMV 0/15 (0%) 0/24 (0%) 0/34 (0%) 11/115 (10%)
EBV load in CSF, copies/mL . 1202 (182–2281) 1102 (365–7269) 6849 (511–223 323)
EBV load in blood, copies/mL NA NA 2874 (1146–201 905) 31 010 (751–35 658 200)
Values are median (range) unless otherwise stated.
Abbreviations: CSF, cerebrospinal fluid; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; HSV 1 & 2, herpes simplex virus
types 1 and 2; NA, not available; PCR, polymerase chain reaction; VZV, varicella zoster virus.
a CD4 count available for 23 patients without meningitis and 45 patients with meningitis.
b Outcome data not available for 7 patients with meningitis.
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load that is associated with outcome rather than just the presence
of virus. We speculate that EBV plays a causative role. EBV
causes neurological damage by direct infection of brain cells or
immune-mediated damage [14, 15]. EBV can also induce cyto-
kines, which may allow further viral reactivation and impaired
clearance of other infections [5]. The presence of EBV in 25% of
HIV-positive patients with normal CSF does show that EBV can
occur in the CSF without causing inflammation; however, all of
these patients had low EBV loads.
CMV was detected in 10% of HIV-positive patients with
bacterial meningitis. The absence of CMV in other patients in-
dicates that detection is associated with inflammation in the CSF
in patients with underlying immunosuppression. CMV neuro-
logical disease usually occurs at CD4 counts ,50 cells/mm3;
however, in our study CMV-positive patients had a median CD4
count of 121 cells/mm3. A previous study showed that detection
of CMV in the CSF of HIV-positive individuals was almost al-
ways associated with autopsy findings of CMV neurological
disease, even when other neurological diseases were likely to be
the primary illness [4]. Our study showed a significant associa-
tion between dual EBV/CMV infection and mortality, suggesting
that dual herpesvirus infections are associated with greater CSF
inflammation and worse outcome [5, 13].
Our study supports the hypothesis that bacterial meningitis
can trigger reactivation of herpesviruses, especially in HIV-
positive patients. This could be further supported by demon-
strating that the virus is replicating and not latent. We have
shown that CSF EBV load and dual EBV/CMV infection are
associated with increased mortality from bacterial meningitis
and propose that this reflects a causative role resulting from
the effects of EBV and CMV on the inflammatory process
responsible for poor outcome.
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